Life Expectancy with Palliative Chemotherapy for Bilobar Multifocal Colorectal Liver Metastases

Baseline Prognosis Without Treatment

Without any treatment, metastatic colorectal cancer to the liver carries a dismal prognosis, with most patients dying within one year 1
More than half of patients who die from colorectal cancer have liver metastases at autopsy, and the liver is the sole site of metastatic disease in one-third of these patients 2, 3
Historical data shows that 5-year survival rates are extremely low in patients with metastatic liver disease who do not undergo surgery 2, 3

The National Comprehensive Cancer Network recommends that patients with bilobar multifocal colorectal liver metastases can expect a median overall survival of approximately 19-24 months with modern palliative chemotherapy 1
5-year survival rates of 10-20% are achievable with palliative chemotherapy alone, particularly in patients whose disease demonstrates favorable biology 1
The European Society for Medical Oncology suggests that the continuum of care approach—ensuring patients receive exposure to all available active cytotoxic agents and biologics across multiple treatment lines—significantly improves overall survival 4

Bilobar disease characteristics, such as the presence of multiple metastases, are associated with more disseminated disease and worse prognosis compared to unilobar disease 2, 3
Synchronous liver metastases (present at initial diagnosis) indicate more aggressive disease with more sites of liver involvement and worse outcomes than metachronous metastases 2, 3, 1
The presence of ≥3 tumors is associated with poor prognosis, according to the National Comprehensive Cancer Network 3, 5
A disease-free interval <12 months correlates with worse outcomes, as reported by the National Comprehensive Cancer Network 3, 5
The presence of metastases outside the liver significantly worsens prognosis, according to the National Comprehensive Cancer Network 2, 3

If initially unresectable bilobar metastases become resectable after downsizing with chemotherapy (conversion therapy), surgical resection can achieve 5-year survival rates of 20-45%, as suggested by the European Society for Medical Oncology 4, 1
The goal of initial treatment should be to assess potential for conversion to resectable disease through aggressive combination chemotherapy with or without targeted biologics, according to the National Comprehensive Cancer Network 5, 6

Combination chemotherapy doublets (fluoropyrimidine plus oxaliplatin or irinotecan) with or without biologics (bevacizumab or anti-EGFR antibodies in RAS wild-type tumors) represent standard first-line approaches, as recommended by the European Society for Medical Oncology 4
Maintenance therapy with fluoropyrimidine plus bevacizumab after initial combination chemotherapy prolongs progression-free survival compared to complete treatment breaks, according to the European Society for Medical Oncology 4
Exposure to all available active agents across multiple treatment lines improves overall survival, as suggested by the European Society for Medical Oncology 4

Assuming all bilobar disease is incurable: Even extensive bilobar metastases may become resectable with effective chemotherapy, potentially offering long-term survival or cure, as reported by the European Society for Medical Oncology 6, 1
Prophylactic resection of asymptomatic primary: In patients with unresectable metastatic disease and an asymptomatic primary tumor, upfront chemotherapy is preferred over prophylactic resection of the primary, according to the European Society for Medical Oncology 7
Prolonged chemotherapy beyond conversion: Once metastases become technically resectable, surgery should be performed promptly, as unnecessary prolonged chemotherapy increases liver toxicity and postoperative morbidity, as suggested by the European Society for Medical Oncology 6
Underestimating survival potential: While median survival is 19-24 months, a subset of patients achieves much longer survival, particularly those who respond well to chemotherapy or achieve conversion to resectable disease, according to the National Comprehensive Cancer Network 1